诺莫可潘治疗大疱性类天疱疮的评估:一项2a期非随机对照试验
这项多中心、单组、2a期非随机对照试验在荷兰和德国的大学皮肤科开展,纳入9例55岁及以上轻中度新发或复发大疱性类天疱疮患者,给予诺莫可潘90mg皮下注射(第1天)后每日30mg至第42天。结果显示未发现与诺莫可潘相关的严重不良事件,BPDAI活动度评分从第1天32.0分降至第42天19.6分,7/9例(77.8%)应答。作者认为诺莫可潘耐受性良好,可能有助于抑制急性发作,但需更大规模安慰剂对照随机临床试验确认。
要点
- 9例患者中未发现与诺莫可潘相关的严重不良事件。
- 7/9例(77.8%)患者BPDAI活动度评分在第1天至第42天间至少降低8分。
- 3例应答者BPDAI活动度评分降低80%或以上。
核心结论
- 这项非随机对照试验结果提示,诺莫可潘在老年大疱性类天疱疮患者中耐受性良好,可能对抑制该病急性发作有治疗益处。
- 需要更大规模的安慰剂对照随机临床试验来确认其安全性特征,并确立诺莫可潘作为大疱性类天疱疮新治疗选择。
研究设计与样本
- 多中心、单组、2a期非随机对照试验,在荷兰和德国的大学皮肤科开展。
- 参与者于2018年9月至2020年4月入组,为55岁及以上轻中度新发或复发大疱性类天疱疮患者。
- 共纳入9例患者,中位(范围)年龄75(55-85)岁,其中女性5例(55.6%)。
- 干预为诺莫可潘第1天90mg皮下注射,之后每日30mg皮下注射至第42天。
主要发现
- 未发现与诺莫可潘相关的严重不良事件。
- 平均(90% CI)BPDAI活动度评分从第1天32.0(8.7)分降至第42天19.6(9.0)分。
- 9例中7例(77.8%)在第1天至第42天间BPDAI活动度评分至少降低8分,其中3例应答者降低80%或以上。
- 第42天平均(90% CI)BPDAI瘙痒评分较第1天17.6(4.0)分降低6.8(4.6)分。
- 平均(90% CI)DLQI评分从基线11.3(4.2)分降至第42天6.4(3.8)分,TABQOL评分从基线14.6(5.4)分降至第42天10.3(5.0)分。
临床怎么用
- 原文结论指出诺莫可潘在老年大疱性类天疱疮患者中耐受性良好,可能对抑制急性发作有治疗益处,但需更大规模安慰剂对照随机临床试验确认。
局限性
- 原文结论指出需要更大规模的安慰剂对照随机临床试验来确认安全性特征并确立诺莫可潘作为新治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Bullous pemphigoid is a difficult-to-treat autoimmune blistering skin disease that predominantly affects older adults and is associated with an increased mortality rate. OBJECTIVE: To examine the safety and therapeutic potential of nomacopan, an inhibitor of leukotriene B4 and complement C5, in patients with bullous pemphigoid. DESIGN, SETTING, AND PARTICIPANTS: This multicenter, single-group, phase 2a nonrandomized controlled trial was conducted in the dermatology departments of universities in the Netherlands and Germany. Participants were enrolled between September 2018 and April 2020. Older adult patients (aged ≥55 years) with mild to moderate, new-onset or relapsing bullous pemphigoid were recruited into the study. INTERVENTIONS: Patients received nomacopan, 90 mg, subcutaneously on day 1 and 30 mg subcutaneously daily until day 42. MAIN OUTCOMES AND MEASURES: The primary end point was the proportion of patients with grade 3 to 5 (severe) adverse events associated or possibly associated with nomacopan. Secondary end points included mean absolute and percentage changes in the Bullous Pemphigoid Disease Area Index (BPDAI) activity score, the BPDAI pruritus score, and the patient-reported outcome measures Dermatology Life Quality Index (DLQI) and Treatment of Autoimmune Bullous Disease Quality of Life (TABQOL). RESULTS: A total of 9 patients (median [range] age, 75 [55-85] years) with bullous pemphigoid were included in the trial, of whom 5 were women (55.6%). No serious adverse events associated with nomacopan were found. The mean (90% CI) BPDAI activity score decreased from 32.0 (8.7) points on day 1 to 19.6 (9.0) points on day 42. Seven of 9 patients (77.8%) responded to nomacopan with a reduction in the BPDAI activity score of at least 8 points between days 1 and 42; in 3 responders, the reduction was 80% or greater. On day 42, the mean (90% CI) BPDAI pruritus score had decreased by 6.8 (4.6) points from 17.6 (4.0) points on day 1. The mean (90% CI) DLQI score decreased from 11.3 (4.2) points at baseline to 6.4 (3.8) points by day 42, and the mean (90% CI) TABQOL score decreased from 14.6 (5.4) points at baseline to 10.3 (5.0) points on day 42. CONCLUSIONS AND RELEVANCE: Results of this nonrandomized controlled trial suggest that nomacopan can be well tolerated in older patients with bullous pemphigoid and may have therapeutic benefits for suppressing acute flares of this disease. A larger, placebo-controlled randomized clinical trial is warranted to confirm this safety profile and to establish nomacopan as a new therapeutic option for bullous pemphigoid. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04035733.
引用
- Sadik CD, Rashid H, Hammers CM, et al. Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022. PMID: 35507334. doi:10.1001/jamadermatol.2022.1156
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。